drugset / Trial / NCT05649020

ED50 of Intratecal Prilocaine in Ultrasound Fusion Prostate Biopsy

NCT05649020

NaSequentialOpen-labelOther

Summary

The aim of the present study was to determine the ED50 and ED90 of intrathecal hyperbaric 2% prilocaine (HP) for patients undergoing ambulatory prostate biopsy via magnetic resonance imaging (MRI)/ultrasound fusion.

Timeline

Start
2022-11-24
Primary completion
2023-12-31
Completion
2024-03-31

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject prilocaine Small molecule 20 mg Intrathecal

Indications

No indication recorded.